{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:06:16Z","timestamp":1790269576142,"version":"4.1.0"},"reference-count":37,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":253,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The incidence of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) is rising, yet their biological heterogeneity and variable response to treatments remain poorly understood. Comprehensive genomic characterization may uncover somatic drivers and inform biomarker-driven therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed clinically ordered next-generation sequencing (NGS) results from tumor samples of 111 patients with confirmed GEP-NENs treated at Johns Hopkins Hospital between 2020 and 2022. Pathogenic and likely pathogenic mutations were identified using OncoKB, CHASMplus, and COSMIC databases. Mutational patterns were correlated with clinical characteristics and overall survival using univariate and multivariate analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In this retrospective study of 111 patients with gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), somatic pathogenic or likely pathogenic mutations were identified in 79% of cases. The most frequent alterations involved TP53 (19%), MEN1 (17%), and chromatin remodeling genes, such as DAXX (9%) and ATRX (6%). Notably, we also identified a subset of patients (9%) with mutations typically associated with hematologic malignancies. Distinct co-mutation and mutual exclusivity patterns were observed between pancreatic and non-pancreatic NENs. Poorly differentiated or high-grade tumors correlated with mutations in TP53, KRAS, and CDKN2A. Mutations in KRAS, DAXX\/ATRX, and hematologic malignancy-associated genes were independently associated with worse overall survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study reveals distinct somatic mutation patterns in GEP-NENs associated with tumor differentiation, grade, primary site, and survival. The identification of hematologic malignancy-associated mutations in a subset of GEP-NENs suggests possible shared molecular phenotypes with poor prognostic implications. The presence of KRAS mutations supports exploring pan-RAS inhibitors as potential therapies in select patients. These findings highlight the clinical utility of genomic profiling in GEP-NENs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/eo-26-0044","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:26:24Z","timestamp":1789133184000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-15","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive somatic profiling of gastroenteropancreatic neuroendocrine neoplasms"],"prefix":"10.1530","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5825-3356","authenticated-orcid":true,"given":"Chirayu","family":"Mohindroo","sequence":"first","affiliation":[{"name":"Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa 1 , , ,","place":["Iowa City, Iowa, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parul","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Oncology, Abramson Cancer Center at The University of Pennsylvania 2 , , ,","place":["Philadelphia, Pennsylvania, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Oncology, Johns Hopkins University School of Medicine 3 , , ,","place":["Baltimore, Maryland, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"He","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Johns Hopkins University School of Medicine 4 , , ,","place":["Baltimore, Maryland, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Anders","sequence":"additional","affiliation":[{"name":"Department of Pathology, The Johns Hopkins University School of Medicine 5 , , ,","place":["Baltimore, Maryland, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Bever","sequence":"additional","affiliation":[{"name":"Department of Oncology, Johns Hopkins University School of Medicine 3 , , ,","place":["Baltimore, Maryland, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Laheru","sequence":"additional","affiliation":[{"name":"Department of Oncology, Johns Hopkins University School of Medicine 3 , , ,","place":["Baltimore, Maryland, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3225-3024","authenticated-orcid":true,"given":"Ana","family":"De Jesus-Acosta","sequence":"additional","affiliation":[{"name":"Department of Oncology, Johns Hopkins University School of Medicine 3 , , ,","place":["Baltimore, Maryland, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"2026092412364193700_bib1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1001\/jamaoncol.2024.5937","article-title":"Gastroenteropancreatic neuroendocrine tumor incidence by sex and age in the US","volume":"11","author":"Abboud","year":"2025","journal-title":"JAMA Oncol"},{"key":"2026092412364193700_bib2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026092412364193700_bib3","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.3390\/diagnostics14121289","article-title":"Biochemical markers for neuroendocrine tumors: traditional circulating markers and recent development-a comprehensive review","volume":"14","author":"Franchina","year":"2024","journal-title":"Diagnostics"},{"key":"2026092412364193700_bib4","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.3390\/jcm11133794","article-title":"The increasing incidence of neuroendocrine neoplasms worldwide: current knowledge and open issues","volume":"11","author":"Rossi","year":"2022","journal-title":"J Clin Med"},{"key":"2026092412364193700_bib5","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.hoc.2022.07.005","article-title":"Genetics of pancreatic neuroendocrine tumors","volume":"36","author":"Mohindroo","year":"2022","journal-title":"Hematol Oncol Clin"},{"key":"2026092412364193700_bib6","article-title":"Genomic landscape of pancreatic neuroendocrine tumors and implications for clinical practice","volume":"8","author":"De Jesus-Acosta","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"2026092412364193700_bib7","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nature21063","article-title":"Whole-genome landscape of pancreatic neuroendocrine tumours","volume":"543","author":"Scarpa","year":"2017","journal-title":"Nature"},{"key":"2026092412364193700_bib8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1158\/1940-6207.CAPR-23-0483","article-title":"Germline testing identifies pathogenic\/likely pathogenic variants in patients with pancreatic neuroendocrine tumors","volume":"17","author":"Mohindroo","year":"2024","journal-title":"Cancer Prev Res"},{"key":"2026092412364193700_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: a precision oncology knowledge base","volume":"2017","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"2026092412364193700_bib10","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1158\/2159-8290.CD-23-0467","article-title":"Quantifying the expanding landscape of clinical actionability for patients with cancer","volume":"14","author":"Suehnholz","year":"2024","journal-title":"Cancer Discov"},{"key":"2026092412364193700_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cels.2019.05.005","article-title":"CHASMplus reveals the scope of somatic missense mutations driving human cancers","volume":"9","author":"Tokheim","year":"2019","journal-title":"Cell Syst"},{"key":"2026092412364193700_bib12","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: the catalogue of somatic mutations in cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"2026092412364193700_bib13","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1182\/blood-2015-12-688705","article-title":"Comprehensive mutational profiling of core binding factor acute myeloid leukemia","volume":"127","author":"Duployez","year":"2016","journal-title":"Blood"},{"key":"2026092412364193700_bib14","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1182\/blood.V112.11.648.648","article-title":"The BCL9 oncogene promotes tumor progression by conferring enhanced proliferative, metastatic and angiogenic properties to myeloma cells","volume":"112","author":"Mani","year":"2008","journal-title":"Blood"},{"key":"2026092412364193700_bib15","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1182\/blood-2018-99-119038","article-title":"KMT2D is a haploinsufficient tumor suppressor in acute leukemia","volume":"132","author":"Xu","year":"2018","journal-title":"Blood"},{"key":"2026092412364193700_bib16","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/bioinformatics\/btz931","article-title":"ShinyGO: a graphical gene-set enrichment tool for animals and plants","volume":"36","author":"Ge","year":"2019","journal-title":"Bioinformatics"},{"key":"2026092412364193700_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00267","article-title":"Real-time genomic characterization of metastatic pancreatic neuroendocrine tumors has prognostic implications and identifies potential germline actionability","volume":"2018","author":"Raj","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"2026092412364193700_bib18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41416-024-02705-8","article-title":"Comprehensive genomic and transcriptomic characterization of high-grade gastro-entero-pancreatic neoplasms","volume":"131","author":"Angerilli","year":"2024","journal-title":"Br J Cancer"},{"key":"2026092412364193700_bib19","doi-asserted-by":"crossref","first-page":"5943","DOI":"10.1158\/1078-0432.CCR-20-1804","article-title":"Comprehensive genomic profiling of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs)","volume":"26","author":"Puccini","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026092412364193700_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/ERC-21-0152","article-title":"The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms","volume":"29","author":"Venizelos","year":"2022","journal-title":"Endocr Relat Cancer"},{"key":"2026092412364193700_bib21","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41416-024-02773-w","article-title":"Treatment outcome according to genetic tumour alterations and clinical characteristics in digestive high-grade neuroendocrine neoplasms","volume":"131","author":"Elvebakken","year":"2024","journal-title":"Br J Cancer"},{"key":"2026092412364193700_bib22","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.18632\/oncotarget.27265","article-title":"Multiplatform profiling of pancreatic neuroendocrine tumors: correlative analyses of clinicopathologic factors and identification of co-occurring pathogenic alterations","volume":"10","author":"Gong","year":"2019","journal-title":"Oncotarget"},{"key":"2026092412364193700_bib23","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1053\/j.gastro.2018.02.026","article-title":"Loss of chromatin-remodeling proteins and\/or CDKN2A associates with metastasis of pancreatic neuroendocrine tumors and reduced patient survival times","volume":"154","author":"Roy","year":"2018","journal-title":"Gastroenterology"},{"key":"2026092412364193700_bib24","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s40618-025-02552-1","article-title":"Clinical and biological heterogeneity of grade 2 digestive neuroendocrine neoplasms: prognostic significance of the 10% Ki-67 index cutoff and implications for treatment strategies. A longitudinal study","volume":"48","author":"Massironi","year":"2025","journal-title":"J Endocrinol Investig"},{"key":"2026092412364193700_bib25","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40618-022-01961-w","article-title":"Sporadic and MEN1-related gastrinoma and Zollinger-Ellison syndrome: differences in clinical characteristics and survival outcomes","volume":"46","author":"Massironi","year":"2023","journal-title":"J Endocrinol Investig"},{"key":"2026092412364193700_bib26","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13256","article-title":"Impact of KRAS and BRAF mutations on treatment efficacy and survival in high-grade gastroenteropancreatic neuroendocrine neoplasms","volume":"35","author":"Elvebakken","year":"2023","journal-title":"J Neuroendocrinol"},{"key":"2026092412364193700_bib27","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/his.14252","article-title":"Driver mutations occur frequently in metastases of well-differentiated small intestine neuroendocrine tumours","volume":"78","author":"Samsom","year":"2021","journal-title":"Histopathology"},{"key":"2026092412364193700_bib28","article-title":"The first case report of effective treatment with Sotorasib for metastatic atypical lung carcinoid harboring KRAS G12C mutation and aggressive disseminated lung metastasis: a case report","volume":"5","author":"Saiki","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"2026092412364193700_bib29","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1200\/JCO.2025.43.4_suppl.722","article-title":"Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)","volume":"43","author":"Garrido-Laguna","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026092412364193700_bib30","first-page":"391","article-title":"Glimmers of hope for targeting oncogenic KRAS-G12D","volume":"30","author":"Tang","year":"2023","journal-title":"Cancer Gene Ther"},{"key":"2026092412364193700_bib31","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1158\/1078-0432.CCR-22-2598","article-title":"CHIP happens: clonal hematopoiesis of indeterminate potential and its relationship to solid tumors","volume":"29","author":"Reed","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026092412364193700_bib32","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa2413361","article-title":"Tumor-infiltrating clonal hematopoiesis","volume":"392","author":"Pich","year":"2025","journal-title":"N Engl J Med"},{"key":"2026092412364193700_bib33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccell.2019.06.005","article-title":"Pan-cancer convergence to a small-cell neuroendocrine phenotype that shares susceptibilities with hematological malignancies","volume":"36","author":"Balanis","year":"2019","journal-title":"Cancer Cell"},{"key":"2026092412364193700_bib34","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11864-026-01379-z","article-title":"Management of peptide receptor radionuclide therapy toxicities in neuroendocrine neoplasm patients","volume":"27","author":"Mohindroo","year":"2026","journal-title":"Curr Treat Options Oncol"},{"key":"2026092412364193700_bib35","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"2026092412364193700_bib36","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41392-021-00701-5","article-title":"Wnt\/\u03b2-catenin signaling in cancers and targeted therapies","volume":"6","author":"Yu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2026092412364193700_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2015.11.006","article-title":"DNA-repair defects in pancreatic neuroendocrine tumors and potential clinical applications","volume":"44","author":"Liu","year":"2016","journal-title":"Cancer Treat Rev"}],"container-title":["Endocrine Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article-pdf\/doi\/10.1530\/EO-26-0044\/525244\/eo-26-0044.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article-pdf\/doi\/10.1530\/EO-26-0044\/525244\/eo-26-0044.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:36:50Z","timestamp":1790267810000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article\/6\/1\/e260044\/78201\/Comprehensive-somatic-profiling-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1530\/eo-26-0044","relation":{},"ISSN":["2634-4793"],"issn-type":[{"value":"2634-4793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"article-number":"e260044"}}